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We analysed the clinical features and outcome of young patients with non-Ewing’s flat bone sarcoma treated during the era of
contemporary chemotherapy. The characteristics and outcome of 25 patients (15 males and 10 females) with primary or radiation-
related flat bone sarcoma treated in the Pediatrics Department at the Institut Gustave Roussy from 1981 to 1999 were reviewed. In
all, 20 patients had osteosarcoma, four chondrosarcoma and one malignant fibrous histiocytoma. The age at diagnosis ranged from 2
to 23 years (median, 15 years). Nine tumours were located in the craniofacial bones, 11 in the pelvis and five in flat bones at other
sites. Four patients had metastatic disease at diagnosis. Radiation-associated flat bone osteosarcoma was diagnosed in 10 out of 25
cases. The projected overall survival and event-free survival (EFS) rates at 5 years were 45.1 and 34.3% for all the 25 patients. The EFS
rate of patients with second bone sarcoma was similar to that of patients with de novo flat bone sarcoma (P¼0.1). The aim of
treatment was curative for 24 patients, 23 of whom were treated with intensive chemotherapy regimens and 19 with surgery.
Significant adverse prognostic factors on survival included incomplete surgical resection (P¼0.001) and use of regimens without pre-
and postoperative chemotherapy (P¼0.007). Nine of the 25 patients were treated with pre- and postoperative chemotherapy and
complete surgical resection. Among them, eight are alive with no disease. Radical surgical resection is the overriding prognostic factor
for flat bone sarcomas in young patients. Nevertheless, our results suggest a more favourable outcome since the advent of intensive
chemotherapy.
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Malignant bone tumours are the sixth most common malignant
neoplasms in children, accounting for approximately 5% of
childhood malignancies (Young and Miller, 1975; Bernard et al,
1993). With the exception of Ewing’s sarcoma, other primary flat
bone sarcomas (osteosarcoma, malignant fibrous histiocytoma and
chondrosarcoma) are rare in children and adolescents, and their
incidence increases with advancing age (Boland and Huvos, 1986;
Goorin et al, 1987; Huvos and Marcove, 1987; Tucker et al, 1987;
Young et al, 1990). In contrast, bone sarcoma occurring as a
second malignant neoplasm after irradiation is more likely to arise
in flat bones of the axial skeleton than are de novo bone sarcomas
(Weatherby et al, 1981; Huvos et al, 1985; Stea et al, 1987; Pratt
et al, 1997; Tabone et al, 1999).
Advances in the treatment of primary osteogenic sarcoma of the
extremities, and the demonstrated major impact of multiagent
adjuvant chemotherapy in randomised trials, have markedly
improved relapse-free survival (Link et al, 1986; Eilber et al,
1987; Saeter et al, 1991; Meyers et al, 1992; Meyer et al, 2001).
However, the majority of studies generally excluded patients with
osteosarcoma or other primary sarcomas of flat bones. Very
limited information is available about the clinical behaviour and
management of primary or radiation-related flat bone sarcomas in
children or adolescents (Kellie et al, 1990; Kawai et al, 1998; Maes
et al, 1998; Daw et al, 2000; Duffaud et al, 2000). Moreover, most of
the published studies pooled pediatric and adult patients, and
began before the era of intensive chemotherapy (Kellie et al, 1990;
Daw et al, 2000). We described the outcome of pediatric and
adolescent patients, on the one hand, because some studies
suggested age as a prognostic factor (Raymond et al, 1987; Saeter
et al, 1996), with a more favourable outcome in children and
adolescents, and, on the other hand, because during the era of
modern chemotherapy, pediatric and adult patients were treated
according to different protocol.
To better define the natural history of these tumours and to
propose management recommendations for children, we analysed
the clinical characteristics, treatment modalities and outcome
of 25 young patients with primary or radiation-related flat bone
sarcoma (other than Ewing’s sarcoma) treated in the Pediatrics
Department at the Institut Gustave Roussy from 1981 to 1999.
During this period, all patients were treated according to intensive
chemotherapy: T10 protocol or modified T10 protocol (Kalifa et al,
1993).
PATIENTS AND METHODS
From January 1981 to January 1999, 440 consecutive patients were
admitted to the Pediatrics Department at the Institut Gustave Revised 15 October 2003; accepted 18 November 2003
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lRoussy for treatment of bone sarcomas other than Ewing’s
sarcoma. This group comprised children and adolescents diag-
nosed as having osteosarcoma (422), chondrosarcoma (14),
malignant fibrous histiocytoma (3) and fibrosarcoma (1). Of these
440 patients, 29 were treated for flat bone sarcoma (representing
6.6% of all patients with non-Ewing’s sarcoma of bone). Of these
29 patients, four were inevaluable because of treatment refusal and
inadequate follow-up in one, and three were lost to follow-up. This
retrospective analysis therefore concerns 25 children and adoles-
cents. It reports on the outcome of patients as of April 2001, 15
months after the inclusion of the last case.
The diagnosis of flat bone sarcoma was based on conclusive
clinical and imaging findings that were always confirmed by
histological analysis. The initial work-up to determine the extent of
the primary tumour and the presence of metastatic disease
included computed tomography (CT) scan of the primary site
(n¼25) and chest (n¼25), magnetic resonance imaging (MRI) of
the primary site (n¼20), conventional chest radiography (n¼25)
and technetium-99m-diphosphonate bone scan (n¼25). All
available histologic material was reviewed by one of us (JMG),
who classified the tumours according to the World Health
Organization (WHO) histologic typing of bone tumours (Contesso
et al, 1987; Forest, 1995).
Response to preoperative chemotherapy, based on conclusive
clinical and imaging findings (conventional radiography and CT
scan of the primary site and metastases, skeletal scintigraphy and
MRI of the primary site), was evaluated before surgical excision of
the primary tumour. The overriding response criteria were,
however, histopathologic findings after surgery. The surgical
margin was defined as the closest margin between the tumour
and the dissection plane. It was identified based on the description
of the Musculoskeletal Tumor Society (Enneking, 1986). Surgical
procedures were defined as a biopsy when an incisional biopsy was
performed, as incomplete resection when tumour invasion of
surgical margins was proven histologically, and as complete
resection when tumour-free surgical margins were histologically
confirmed. Response to preoperative chemotherapy was assessed
in resected tumours by histologically grading the degree of
tumour necrosis in the surgical specimen according to the
method proposed by Huvos et al (Huvos et al, 1977; Rosen et al,
1982).
Follow-up was calculated from the time of diagnosis to the last
contact. Actuarial survival curves were plotted from the diagnosis
of flat bone sarcoma using the Kaplan–Meir method (Kaplan and
Meier, 1958; Meyer et al, 1992). Survival distribution comparisons
were performed using the logrank test. Analysis of the variables
influencing survival was performed using a Cox proportional
hazards model (Dixon, 1988).
RESULTS
Patient characteristics
A total of 25 children and adolescents (15 males and 10 females)
treated in the Pediatrics Department were included in this
retrospective study. Patient characteristics are listed in Table 1.
The median age was 15 years (range 2–23). Nine tumours were
located in the craniofacial bones, 11 in the pelvis and five in flat
bones at other sites. When more than one bone was involved, the
bone predominantly involved was considered as the primary site.
The histological types in this group of children and adolescents
were osteosarcoma (20), chondrosarcoma (four) and malignant
fibrous histiocytoma (one). At diagnosis, four patients (16%)
presented with metastases in the lungs only (two), in the lungs and
bones (one) and in the lungs and subcutaneous tissue (one).
Secondary flat bone osteosarcoma within a previously irradiated
site was diagnosed in 10 cases (40%).
Radiation-related osteosarcoma
All postradiation osteosarcoma developed within the radiation
field. The type of primary tumour is listed in Table 2. The median
time between radiotherapy and the diagnosis of the secondary
bone sarcoma was 7 years (range 3–15). The sites of postirradia-
tion tumours were the craniofacial bones (five), the pelvis (three),
the clavicle (one) and the scapula (one). Distant metastases were
not identified at diagnosis in any of these 10 patients. The median
dose of radiation administered within the target volume where the
secondary bone sarcoma had developed was 40Gy (range 15–65).
Eight of these 10 patients had also received prior therapy with
alkylating agents (Table 2).
Histopathologic findings
Upon review, 19 of the 25 tumours were classified as osteosarco-
mas (Table 1). The slide of the tumour in one additional patient
was not available for central review. Notwithstanding, the
microscopic description recorded on the pathology report of this
patient corresponded to the diagnosis of osteosarcoma. Histologic
subtyping was available for 12 of 19 flat bone osteosarcomas. The
predominant histologic subtypes in these 12 tumours were
chondroblastic (five cases), osteoblastic (one), fibroblastic (one)
and mixed chondroblastic and osteoblastic (four). The last patient
(patient 23) had a small cell osteosarcoma. Concerning the seven
patients for whom histologic subtyping was not available, five had
a craniofacial tumour and two a pelvis tumour.
Four patients in this series had chondrosarcoma that were
poorly differentiated in two cases and well differentiated in two.
The last patient (patient 21) had a typical malignant fibrous
histiocytoma.
Therapy and outcome
The treatment of patients with flat bone sarcoma is listed in
Table 1. One patient (no. 4) was exclusively treated with a palliative
intent. He had a large tumour involving the pelvis and thigh, which
prohibited surgical excision. He died of disease progression 4
months after the diagnosis.
The 24 remaining patients were treated with a curative intent.
One patient (no. 19), who underwent incomplete surgical resection
followed by radiotherapy, relapsed 3 years later and died. Intensive
chemotherapy regimens were administered to 23 patients, three of
whom (nos. 3, 21, 22) only received postoperative chemotherapy.
Surgical resection had been incomplete in these three patients who
received regimens containing high-dose methotrexate (HDMTX)
postoperatively. All the three died of disease. The 20 remaining
patients received chemotherapy as first-line treatment. Only
chemotherapy and radiotherapy were used to treat the primary
tumour in five of them (nos. 5, 10, 17, 18, 23), with HDMTX in
three out of five. Surgical excision of the primary tumour was
impossible in four of the five patients due to early progression,
despite second-line therapy with cisplatin, ifosfamide and
doxorubicin. Three of them died of disease (11, 11 and 8 months
post diagnosis). The fourth patient (no. 10) is alive with
progressive disease 2.5 years after diagnosis. The last patient (no.
23), who had small-cell osteosarcoma of the first vertebra, was
treated according to the protocol for metastatic Ewing’s sarcoma
(Sandoval et al, 1996). Having achieved a complete remission at all
metastatic sites on first-line chemotherapy, he was consolidated
with high-dose chemotherapy (HDC) followed by stem cell
transplantation (SCT) and irradiation to the primary site. He is
alive and free of disease with a follow-up of 8 years. Three patients
(nos. 8, 14, 16) were treated with preoperative chemotherapy and
surgery: one of them (no. 8) had a complete surgical resection after
one course of HDMTX (12gm
 2), and is alive and free of disease
with a follow-up of 4 years. In the two others (nos. 14, 16),
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courses of chemotherapy, respectively. They both relapsed rapidly
and died of disease 6 and 7 months after the diagnosis.
The 12 remaining patients received chemotherapy before and
after surgical resection. Of them, 11 received regimens containing
high-dose methotrexate (HDMTX; 8–12gm
 2) according to the
modified T10 protocol (Rosen et al, 1982) with two to eight
(median 7) preoperative HDMTX courses as first-line chemother-
apy. The 12th patient (no. 20), who had malignant fibrous
histiocytoma, was treated with a combination of ifosfamide,
vincristine and actinomycin in three preoperative courses, but
failed to achieve a measurable response. He received three courses
of doxorubicin and cisplatin, and two courses of HDMTX as
second-line chemotherapy, but again no response was observed.
Of these 12 patients, 11 were assessable for a histologic response
to preoperative chemotherapy. The postoperative results and
details are listed in Table 3. Surgical resection was microscopically
complete in eight of the 12 patients. Seven of them (nos. 2, 6, 9, 11,
12, 24 and 25) are alive and free of disease, with a follow-up of 3–
11.5 years, and one (no. 7) relapsed 31 months post diagnosis and
Table 1 Patient characteristics and outcome
Treatment
Patient
no. Sex
Age at
diagnosis
(year)
Primary
site Metastases
Histologic
type Chemotherapy Surgery Radiotherapy
Pattern of
failure
Outcome/
follow-up
Pelvis
1
* F 20 SACRUM No OST (F) Pre- and
postoperative
Incomplete resection 55Gy Local+
metastatic
DOD/17 months
2
* F 10 ISCHIUM No OST Pre- and
postoperative
Resection No NED/3.5 years
3 M 16 ILIUM No OST (C) Postoperative Incomplete resection No Local DOD/2.5 years
4 M 15 ILIUM No OST (C) Palliative No 16Gy
(neutron)
DOD/4 months
5 F 15 ILIUM Yes CHON Yes No 40Gy
(palliative)
DOD/11 months
6 M 16 ILIUM No CHON Pre- and
postoperative
Resection No NED/6.5 years
7 M 15 ISCHIUM No OST (C) Pre- and
postoperative
Resection 25Gy
(neutron)
Local +
metastatic
DOD/3.5 years
35Gy
(palliative)
8 M 17 ILIUM No CHON Preoperative Resection No NED/4 years
9 F 13 ILIUM No OST (O) Pre- and
postoperative
Resection No NED/3 years
10 F 16 SACRUM No OST Yes No 40Gy Local PD/2.5 years
30Gy (neutron)
11
* M 15 ILIUM No OST Pre- and
Postoperative
Resection No Local NED/11.5 years
Craniofacial
12
* M 23 MANDIBLE No OST Pre- and
postoperative
Hemimandibulectomy No NED/5.5 years
13
* M 15 OCCIPUT No OST (M) Pre- and
postoperative
Incomplete resection No Local DOD/2 years
14 F 9 MANDIBLE Yes OST (M) Preoperative Hemimandibulectomy No Local DOD/6 months
15 M 16 MANDIBLE Yes OST Pre- and
postoperative
Hemimandibulectomy 55Gy Local +
metastatic
NED/8.5 years
16
* M 18 MANDIBLE No OST (M) Preoperative Hemimandibulectomy No Local +
metastatic
DOD/7 months
17
* M 17 MAXILLA No OST Yes No No DOD/11 months
18
* F 7 ZYGOMA No OST Yes No No DOD/8 months
19 F 12 MAXILLA No OST No Incomplete resection 56Gy Local DOD/3 years
20 F 2 MAXILLA No MFH Pre- and
postoperative
Zygoma and maxilla
Incomplete resection
No NED/5 years
Other sites
21 M 17 VERTEBRA No OST (C) Postoperative Incomplete resection 22Gys
(telecobalt)
Local DOD/2 years
50Gys
22 F 4 VERTEBRA No CHON Postoperative Incomplete resection 45Gys Local DOD/4.5 years
22Gys
(palliative)
23 M 12 VERTEBRA Yes OST (m) Yes (HDC) No 40Gys NED/8 years
24
* M 17 CLAVICLE No OST (M) Pre- and
postoperative
Cleidectomy No NED/9 years
25
* M 15 SCAPULA No OST (C) Pre- and
postoperative
Scapulectomy No NED/11.5 years
*Radiation-induced osteosarcoma; OST¼osteosarcoma; CHON¼chondrosarcoma; MFH¼malignant fibrous histiocytoma; F¼fibroblastic; C¼chondroblastic;
O¼osteoblastic; M¼mixed; m¼microcellular; DOD¼died of disease; NED¼no evidence of disease; PD¼progressive disease.
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ldied. Among the four patients (nos. 1, 13, 15 and 20) in whom
surgery was incomplete, two received postoperative radiotherapy
to the site of the primary tumour (nos. 1, 15). Two of these four
patients died of disease and two are alive with no evidence of
disease, with a follow-up of 5 and 8.5 years, respectively (nos. 15,
20).
Prognostic factors
The outcomes of the 25 patients with flat bone sarcomas are shown
in Figure 1. As of April 2001, 11 out of 25 patients were alive and
disease-free, with a median follow-up of 5.3 years post diagnosis
(range 3–11.5). The projected overall survival (OS) and event-free
survival (EFS) rates at 5 years were 45.1% (719%) and 34.3%
(718%) for all 25 patients with flat bone sarcomas (Figure 1). The
factors likely to influence EFS were studied by univariate analysis
(logrank test). The EFS rate of patients with a secondary bone
sarcoma was similar to that of patients with de novo flat bone
sarcomas (P¼0.1). Sex, age at diagnosis, the site of the primary as
well as detectable metastases at diagnosis had no significant impact
on outcome. With regard to the histologic subtype, eight of the 20
patients with osteosarcoma and two of the four patients with
chondrosarcoma survived. The number of cases per histologic
subtype is, however, too small to allow any statistical comparison.
Of the 12 patients who received preoperative chemotherapy, 11
were assessable for a histologic response. Surprisingly, three of the
five patients with tumour necrosis X95% and five of the six
patients with tumour necrosis o95% survived. Concerning
chemotherapy, the comparison of EFS between patients with or
without pre- and postoperative chemotherapy indicated signifi-
cantly poorer survival in the subgroup without chemotherapy
(P¼0.007). However, the most powerful prognostic indicator was
incomplete surgical resection: indeed, only two of the 10 patients
in whom tumour resection was incomplete survived. Conversely,
eight of the nine patients in whom surgery was complete survived.
EFS was significantly higher in these nine patients (71.1%
(75.5%)/12.5% (710.6%): P¼0.001).
DISCUSSION
We reviewed our institutional experience with flat bone sarcomas,
other than Ewing’s, in order to characterise the clinical findings
and to identify factors that have an impact on outcome. To our
knowledge, this is the first study to focus on pediatric primary and
secondary flat bone sarcomas, during the era of intensive
chemotherapy (Kellie et al, 1990; Kawai et al, 1998; Maes et al,
1998; Daw et al, 2000; Duffaud et al, 2000). Our patient
characteristics were comparable to those of other published
studies (Kellie et al, 1990; Kawai et al, 1998; Maes et al, 1998;
Daw et al, 2000; Duffaud et al, 2000). The median age was 15 years
(range 2–23), confirming that flat bone sarcoma affects older
children more frequently than conventional extremity osteosarco-
ma (Whelan, 1997).
Table 2 Radiation-related flat bone sarcomas
Therapy for primary tumour
Patient no. Primary tumour Chemotherapy RT (Gy) Time to onset (year)
1 Bone giant cell tumour No 15 7.1
2 Nephroblastoma Actino, Doxo 30 3.3
12 Rhabdomyosarcoma VCR, Actino, Doxo 45 7.8
13 Rhabdomyosarcoma VCR, Actino, Doxo, Cyclo 45 13.3
14 Medulloblastoma Etoposide, Cyclo, Carbo 55 6.7
17 Rhabdomyosarcoma VCR, Actino, Cyclo, Procarb 45 15.5
18 Undifferentiated carcinoma of the nasopharyngeal type (UCNT) No 65 14
19 Neuroblastoma VCR, Doxo, Cyclo 30 6.3
26 Hodgkin’s disease VCR, PDN, Procarb, Chlormeth 40 11.8
28 Hodgkin’s disease VCR, PDN, Procarb, Chlormeth 40 9.8
VCR¼vincristine; Actino¼actinomycin; Doxo¼doxorubicin; Cyclo¼cyclophosphamide; Carbo¼carboplatin; Procarb¼procarbazine; PDN¼prednisone; Chlormeth¼
chlormethin; UCNT¼undifferentiated carcinoma of the nasopharyngea type.
Table 3 Results and postoperative treatment according to preoperative chemotherapy
Preoperative chemotherapy
Histologic response
p5% of viable cells Postoperative chemotherapy (No patient)
HDMTX and doxorubicin-containing regimens 0/3 Ifosfamide and cisplatin-containing courses (1, 24, 25)
HDMTX and ifosfamide-containing regimens 5/8 HDMTX and ifosfamide-containing courses for good responders (2, 7, 11, 12, 13)
Ifosfamide and cisplatinum for poor responders (6, 9, 15)
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Figure 1 Survival rates from the diagnosis of flat bone arcomas: ______
Overall survival (n¼25); .............event-free survival (n¼25).
Flat bone sarcomas in children and adolescents
V Minard-Colin et al
616
British Journal of Cancer (2004) 90(3), 613–619 & 2004 Cancer Research UK
C
l
i
n
i
c
a
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which arose in the pelvis and two had high-grade chondrosarcoma.
Our results confirm the poor chemosensitivity and radiosensitivity
of these tumours (Lee et al, 1999; Bergh et al, 2001): one of the two
patients with high-grade chondrosarcoma had a measurable
response after chemotherapy and the only patient in whom
radiotherapy was delivered with a curative intent, relapsed 13
months later and died of disease. The most powerful prognostic
factor concerning flat bone chondrosarcomas appeared to be the
quality of the surgical resection. Among the four patients with
chondrosarcoma, two are alive and disease free and surgical
resection was complete in both of them, whereas the two other
patients died of disease after incomplete surgical resection.
Some studies have already indicated that flat bone osteosarcomas
often respond poorly to chemotherapy and progress in their
treatment has not improved to the same extent as that accomplished
for long bone osteosarcomas (Link et al, 1986; Eilber et al, 1987;
Saeter et al, 1991; Meyers et al, 1992). The chondroblastic variant
has been reported to be somewhat over-represented among flat
bone osteosarcomas. Kellie et al (1990) reported that 37% of 19 flat
bone osteosarcomas were predominantly chondroblastic. In our
study, 20% of the osteosarcomas were predominantly chondroblas-
tic. Chondroblastic variants of osteosarcoma, such as chondrosar-
coma, respond poorly to chemotherapy, with 3–6.1% of total
necrosis after initial chemotherapy (Ozaki et al, 1997; Bacci et al,
1998; Lee et al,1 9 9 9 ;B a c c iet al, 2001; Bergh et al, 2001), whereas
39–52% of extremity osteosarcoma had 495% of tumour necrosis
following preoperative chemotherapy (Sandoval et al, 1996; Bacci
et al, 1998, 2001). The excess incidence of the chondroblastic variant
could then explain the poor chemosensitivity of flat bone
osteosarcomas. Moreover, comparison of flat bone osteosarcoma
and extremity osteosarcoma revealed that osteosarcomas of flat
bones had the worst prognosis.
Evidence reported on the prognosis of secondary osteosarcomas
compared to primary lesions is inconsistent and controversial. In a
recent study, secondary osteosarcomas of the pelvis were found to
be correlated with a poor prognosis (Grimer et al, 1999). In
contrast, Pratt et al (1997) published that the prognosis and overall
outcome of patients with flat bone tumours were comparable for
primary and secondary osteosarcomas. In another study, Tabone
et al (1999) examined 23 cases of radiation-related osteosarcoma
after treatment of childhood cancer. In all, 12 out of 23 patients
were alive with no evidence of disease, and six out of 14 patients
with flat bone osteosarcomas compared to three out of eight in our
study. These results were confirmed by another study (Bielack et al,
1999). The present study appears to confirm that EFS of patients
with secondary bone sarcoma is similar to that of patients with de
novo flat bone sarcomas, and thus confirms that incomplete
surgical resection of the primary tumour is the worst prognostic
factor for flat bone osteosarcomas.
One of the aims of this study was to examine the prognostic
factors usually analysed in flat bone sarcomas. The overall survival
rate at 5 years is 45.1% (719%) for the study population. Other
studies have reported similar 5-year survival rates of between 33
and 47% for patients with pelvic osteosarcoma (Kawai et al, 1998;
Grimer et al, 1999). In our study, the site of the tumour in the
pelvis had no impact on outcome. Kellie et al (1990) reported a
lower 10-year survival rate of 24%. However, their study focused
on the outcome of patients treated between 1962 and 1987, before
the era of intensive chemotherapy.
In contrast to other reported studies in which none of the
patients had metastatic disease at presentation (Kellie et al, 1990),
distant metastases were identified in four patients at diagnosis in
our study. Metastases at diagnosis appeared to have no impact on
outcome, but the number of cases was too small to allow any
statistical comparison.
The efficacy of multidrug chemotherapy for patients with
primary osteosarcoma of long bones amenable to en bloc resection
is well documented (Huvos et al, 1985; Link et al, 1986; Eilber et al,
1987; Saeter et al, 1991; Meyers et al, 1992; Meyer et al, 2001).
Kellie et al (1990) advocate the use of preoperative multiagent
chemotherapy to facilitate surgical resection of non-Ewing’s
sarcomas of flat bone. Duffaud et al (2000) reported no survivors
among eight out of 16 patients who developed metastases, and then
recommended the use of pre- and postoperative chemotherapy. In
our study, patients who received pre- and postoperative
chemotherapy had a significantly better outcome than those who
received another treatment modality (none, neoadjuvant or
adjuvant chemotherapy).
The importance of complete resection in maximising the
chances of prolonged relapse-free survival is supported by many
authors (Kellie et al, 1990; Kawai et al, 1998; Grimer et al, 1999;
Daw et al, 2000; Duffaud et al, 2000; Ferguson et al, 2001; Ozaki
et al, 2002). Kawai et al (1998) identified two prognostic factors in
a multivariate analysis of pelvic bone sarcomas: the type of surgical
resection and the surgical margin. Daw et al (2000) reported that
incomplete resection of osteosarcoma was associated with local
failure and poor outcome in sarcomas of the head and neck. More
recently, Gadwal et al (2001) reported a 5-year survival rate of 72%
for 15 children who underwent surgical resection of primary
osteosarcoma of the head and neck. In the largest study of
sarcomas of flat bones in children and adolescents, Kellie et al
(1990) reported complete surgical excision in 10 out of 28 patients,
eight of whom also received postoperative chemotherapy. Five of
these patients are still disease free. Surgical options for local
control of flat bone osteosarcomas are more limited than for long
bone lesions. Radical surgical resection is often impossible in
critical areas, such as vertebrae, the sacrum or craniofacial bones,
because there is a high risk of functional incapacitation or
cosmetic defects. Concerning sarcoma of the pelvic bones, Kawai
et al (1998) emphasised how it is often difficult to resect such
lesions with wide margins, because of poor compartmentalisation
and the complicated anatomy of the pelvis. Our results confirm
that complete surgical excision is the strongest prognostic factor
concerning flat bone sarcomas. In our study, 19 patients had
surgical resection of the primary tumour (in six patients, surgical
resection was impossible). Eight of nine patients who underwent
complete surgical excision were alive with no evidence of disease,
compared to two of 10 in whom resection of the primary tumour
was incomplete. After complete surgical resection, local recurrence
occurred in 22% of cases. The number of patients is, however, too
small to suggest that local recurrence has an effect on survival.
Adequate local control was achieved in five of the 10 patients in
whom resection was incomplete with additional, external beam,
high-energy RT (Smith, 1982). Local control was prolonged in
these five patients, but only one is still alive with no evidence of
disease, having attained a follow-up of 8.5 years. It is difficult to
assess the role of postoperative radiotherapy, given the hetero-
geneity of each small series.
In conclusion, this study has confirmed that radical surgical
resection is the overriding prognostic factor for flat bone sarcomas
in children and adolescents. Nevertheless, our results suggest a
more favourable outcome since the advent of intensive che-
motherapy. Usually, patients with osteosarcoma of flat bones are
excluded from clinical trials of new adjuvant therapies. Given the
poor response to conventional chemotherapy, new therapeutic
approaches are warranted. We propose the conduct of an
international prospective study with a large population, to evaluate
the role of each treatment modality and to study the specific
biology of these tumours.
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